Difference between revisions of "Maprotiline-tranylcypromine"

From Psychiatrienet
Jump to: navigation, search
 
(6 intermediate revisions by 4 users not shown)
Line 3: Line 3:
 
| to = tranylcypromine  
 
| to = tranylcypromine  
 
| stop =  
 
| stop =  
* '''Before day 0:''' gradually reduce dosage of maprotiline to a maximum of 75 mg/ day, when this dosage is > 75 mg/day.
+
{{generaldecrease25p3d}}
* '''Day 1-3:''' reduce dosage of maprotiline to 50 mg/day.
 
* '''Day 4-7:''' reduce dosage of maprotiline to 25 mg/day.
 
* '''Day 8:''' stop administration of maprotiline.
 
 
| start =  
 
| start =  
* '''Day 8-14:''' a wash-out period of one week is necessary.
+
{{Starttranyl}}
* '''Day 15:''' start administration of tranylcypromine in a low dosage of 20 mg/day for one week.
+
| info =
* '''Day 22:''' after this week the dosage of tranylcypromine can be increased if necessary.}}
+
{{nowashout}}<ref name="informatorium">{{KNMP}}</ref>
 +
}}

Latest revision as of 14:06, 8 March 2024

Maprotiline
Type Antidepressant
Group NRI
links
Medscape Maprotiline
PubChem 4011
PubMed Maprotiline
Kompas (Dutch) Maprotiline
Wikipedia Maprotiline
Tranylcypromine
Type Antidepressant
Group MAO-I
links
Medscape Tranylcypromine
PubChem 5530
PubMed Tranylcypromine
Kompas (Dutch) Tranylcypromine
Wikipedia Tranylcypromine

Switch medication from maprotiline to tranylcypromine.[1] [2]

Nietinrijdenbord.png Stop maprotiline
  • Decrease with about 25% of original dose every 3 days
Eenrichtingbord.png Start tranylcypromine
  • Start tranylcypromine in a low dosage of 20 mg/day for one week.
  • After this week the dosage of tranylcypromine can be increased.
Infobord.png More information
  • No wash-out period is necessary[3]
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. KNMP; Informatorium Medicamentorum 2023; Monografie "{{{1}}}" (Dutch)
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.